3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Breast Neoplasms
12
Triple Negative Breast Neoplasms
5
Ovarian Neoplasms
4
Advanced Solid Tumors
4
Prostatic Neoplasms
3
Pancreatic Neoplasms
3
Neoplasms
3
Fallopian Tube Neoplasms
2
Colorectal Neoplasms
2
Carcinoma, Renal Cell
2
Carcinoma, Ovarian Epithelial
2
mCRPC
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumor
1
Small Cell Lung Carcinoma
1
Sarcoma, Ewing
1
Recurrent Squamous Cell Lung Carcinoma
1
Recurrence
1
Neuroectodermal Tumors, Primitive, Peripheral
1
Neoplasm Metastasis
1
Lung Neoplasms
1
Leukemia, Myeloid, Acute
1
Hereditary Sensory and Autonomic Neuropathies
1
Fanconi Anemia, Complementation Group D1
1
Endometrial Neoplasms
1
Central Nervous System Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Breast Adenocarcinoma
1
Advanced Solid Tumor
1
Advanced Ovarian Cancer
1
Interventions
fludarabine phosphate
15
Whole-Body Irradiation
9
Peripheral Blood Stem Cell Transplantation
9
Mycophenolic Acid
9
Cyclophosphamide
8
Busulfan
8
Tacrolimus
7
Cyclosporine
5
ruxolitinib
4
fludarabine
4
Methotrexate
4
Antilymphocyte Serum
4
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
3
peginterferon alfa-2a
2
givinostat hydrochloride
2
givinostat
2
Stem Cell Transplantation
2
Radiotherapy
2
Melphalan
2
Etoposide
2
Carboplatin
2
veliparib
1
thymoglobulin
1
sonidegib
1
pomalidomide
1
merphos
1
bomedemstat
1
anagrelide
1
Transplantation
1
Topotecan
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Has results
×
Thrombocythemia, Essential
×
talazoparib
×
Clear all
No trials found.